Riverview Trust Co Has $173,000 Stock Position in Becton, Dickinson and Company $BDX

Riverview Trust Co reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,004 shares of the medical instruments supplier’s stock after selling 160 shares during the quarter. Riverview Trust Co’s holdings in Becton, Dickinson and Company were worth $173,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth approximately $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth approximately $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth approximately $31,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock worth $562,036 in the last ninety days. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Up 2.0%

NYSE:BDX opened at $190.90 on Thursday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm has a market cap of $54.72 billion, a price-to-earnings ratio of 34.33, a P/E/G ratio of 1.51 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $188.71 and its 200-day moving average is $188.20.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter last year, the firm posted $3.50 earnings per share. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 74.82%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BDX. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus raised their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.